DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.08
+0.30 (+2.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.78
Open13.00
Bid12.35 x 800
Ask13.08 x 2200
Day's Range12.78 - 13.82
52 Week Range6.98 - 31.42
Volume731,442
Avg. Volume457,950
Market Cap549.705M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-7.62
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Report: Exploring Fundamental Drivers Behind Dermira, California Resources, OGE Energy, Oasis Petroleum, Harmonic, and CBIZ — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire12 days ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on October 8, 2018, the company granted inducement awards to nine new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 8,250 shares of Dermira common stock and stock options to purchase an aggregate of 44,825 shares of Dermira common stock.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding DERM is favorable, with net inflows of $5.72 billion.

  • GlobeNewswire20 days ago

    Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced its collaboration with Council of Fashion Designers of America, Inc. (CFDA) fashion designer Christian Siriano for the Check Your Sweat educational campaign. Check Your Sweat is designed to raise awareness of excessive underarm sweating, or primary axillary hyperhidrosis, a treatable medical condition.

  • GlobeNewswire21 days ago

    Dermira’s QBREXZA™ (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, announced today that QBREXZA™ (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis, commonly known as excessive underarm sweating. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding DERM is favorable, with net inflows of $5.36 billion.

  • GlobeNewswire27 days ago

    Dermira to Present at Cantor 2018 Global Healthcare Conference

    MENLO PARK, Calif., Sept. 25, 2018-- Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions ...

  • GlobeNewswirelast month

    Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today presented data from a post-hoc analysis of the Phase 3 open-label ARIDO study which evaluated the long-term safety of glycopyrronium tosylate in patients with primary axillary hyperhidrosis. The data showed the response of pediatric patients (ages 9 to 16) compared to older patients (ages 17 years and older) with primary axillary hyperhidrosis who received treatment with glycopyrronium tosylate (now QBREXZA™ (glycopyrronium) cloth).

  • GlobeNewswirelast month

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on September 7, 2018, the company granted inducement awards to 116 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 35,550 shares of Dermira common stock and stock options to purchase an aggregate of 77,775 shares of Dermira common stock.

  • GlobeNewswire2 months ago

    Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced several updates related to the upcoming launch and availability of QBREXZA™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Primary axillary hyperhidrosis, also known as excessive underarm sweating, is a chronic medical skin condition that results in sweating beyond what is needed for normal body temperature regulation. “QBREXZA is the culmination of more than 10 years of clinical development work,” said Tom Wiggans, chairman and chief executive officer of Dermira.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold DERM had net inflows of $499 million over the last one-month.

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DERM totaled $1.01 billion.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, ...

  • GlobeNewswire2 months ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on August 7, 2018, the company granted inducement awards to six new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 6,250 shares of Dermira common stock and stock options to purchase an aggregate of 34,600 shares of Dermira common stock.

  • Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates

    Dermira (DERM) delivered earnings and revenue surprises of 0.00% and 0.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Dermira: 2Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 57 cents per share. The skin condition drug developer posted revenue of $39.1 million in the period. Dermira shares have fallen 64 percent ...

  • GlobeNewswire2 months ago

    Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update 

    -QBREXZA™ cloth for the treatment of primary axillary hyperhidrosis approved in June 2018- QBREXZA expected to be available nationwide in pharmacies beginning in October 2018- Lebrikizumab Phase 2 b enrollment ...

  • See what the IHS Markit Score report has to say about Dermira Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DERM totaled $936,846.

  • Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
    Zacks4 months ago

    Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval

    Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.

  • Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?
    Zacks4 months ago

    Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?

    Investors in Dermira (DERM) need to pay close attention to the stock based on moves in the options market lately.

  • FDA Approval Pushes Dermira’s Stock Price Up
    Market Realist4 months ago

    FDA Approval Pushes Dermira’s Stock Price Up

    Today, Dermira (DERM) announced FDA approval for its Qbrexza™ (glycopyrronium) cloth as a treatment option for primary axillary hyperhidrosis or excessive armpit sweating in both adults and pediatric patients above nine years of age. After this announcement, Dermira rose around 5.6% in the morning trading. Dermira estimates that almost 15 million people in the United States suffer from hyperhidrosis, of which 10 million suffer from axillary hyperhidrosis.

  • TheStreet.com4 months ago

    Dermira Shares Soar With FDA Approval of New Cloth

    Shares in the Menlo Park, Calif., biotech company rose 95 cents -- or 9.73% -- to $10.88 a share in early trading Friday after the company reported it had received approval from the U.S. Food and Drug Administration for its new cloth designed to treat patients with excessive underarm sweating. Dermira's Qbrexza topical cloth is the first FDA-approved treatment for people with primary axillary hyperhidrosis, a condition that affects an estimated 10 million people in the U.S. Qbrexza is designed to stop sweat production by "inhibiting sweat gland activity" when the cloth is applied to the skin. "I look forward to Qbrexza's potential to be a meaningful treatment option that will not only reduce a person's sweat but will reduce the overall impact this condition has on their daily life," Dr. Dee Anna Glaser, interim chair of the Department of Dermatology at St. Louis University School of Medicine, said in the statement.

  • FDA OKs first drug made to reduce excessive sweating
    Associated Press4 months ago

    FDA OKs first drug made to reduce excessive sweating

    U.S. regulators on Friday approved the first drug developed specifically to reduce excessive sweating, a common condition that can cause people anxiety and affect their social lives.

  • Reuters4 months ago

    FDA approves Dermira's wipe for excessive armpit sweating

    Dermira Inc said on Friday its topical cloth for excessive armpit sweating was approved by the U.S. Food and Drug Administration, providing patients with an easy-to-use option for an often embarrassing condition. The treatment, Qbrexza, works by blocking receptors responsible for sweat gland activation and can be used once a day, the company said in a statement. About 10 million people are affected with the condition, known as primary axillary hyperhidrosis, which results in sweating beyond what is needed for regulating normal body temperature.